Abstract 1788P
Background
CHART trial has demonstrated the survival benefit of rezvilutamide plus androgen deprivation therapy (ADT) over bicalutamide plus ADT in treating patients with high-volume, metastatic hormone-sensitive prostate cancer (mHSPC). This post-hoc analysis aimed to evaluate the association between achievement of deep PSA decline with survival outcomes in patients with high-volume mHSPC in the CHART trial.
Methods
Patients with high-volume mHSPC were randomly assigned (1:1) to receive ADT plus either rezvilutamide or bicalutamide. PSA kinetics and the association between deep PSA decline (≤0.2 ng/ml) and radiographic progression-free survival (rPFS) and overall survival (OS) in two groups were evaluated.
Results
A total of 654 patients were included in the analysis, with 326 patients in the rezvilutamide plus ADT group, and 328 patients in the bicalutamide plus ADT group. The median PSA nadir levels were 0.02 ng/ml, and 0.68 ng/ml in two groups, respectively. At 6-month, 170 (52.15%) and 90 (27.44%) patients achieved a deep PSA decline, respectively. With a median follow-up of 29.3 months, patients who achieved a deep PSA decline at 6-month had longer rPFS (HR=0.359, 95%CI 0.238, 0.543, P<0.001) and OS (HR=0.339, 95%CI 0.212, 0.540, P<0.001) than those who did not achieve it in the rezvilutamide plus ADT group. Significantly, rezvilutamide plus ADT was found to significantly prolong rPFS compared to bicalutamide plus ADT, regardless of whether patients achieved deep PSA decline at 6-month (HR=0.462, 95%CI 0.283, 0.754, P=0.002) or not (HR=0.587, 95%CI 0.428, 0.804, P<0.001). Table: 1788P
PSA kinetics in CHART trial
| Variables | Rezvilutamide plus ADT (n=326) | Bicalutamide plus ADT (n=328) |
| PSA baseline (ng/ml), median (Q1, Q3) | 78.79 (12.82, 314.80) | 51.32 (8.08, 236.63) |
| PSA nadir (ng/ml), median (Q1, Q3) | 0.02 (0.00, 0.41) | 0.68 (0.08, 3.16) |
| Time to PSA nadir, day, median (Q1, Q3) | 308.0 (169.0, 634.8) | 167.0 (85.0, 281.0) |
| PSA nadir ≤0.2 ng/ml, n (%) | 224 (68.7) | 109 (33.2) |
| Time to PSA ≤0.2 ng/ml, day, median (Q1, Q3) | 392.0 (222.3, 671.0) | 238.0 (141.0, 393.0) |
| PSA ≤0.2 ng/ml at 3-month, n (%) | 125 (38.34) | 58 (17.68) |
| PSA ≤0.2 ng/ml at 6-month, n (%) | 170 (52.15) | 90 (27.44) |
| PSA ≤0.2 ng/ml at 12-month, n (%) | 201 (61.66) | 108 (32.93) |
Conclusions
Rezvilutamide plus ADT resulted in a deep PSA decline, which was associated with improved long-term survival in patients with high-volume mHSPC.
Clinical trial identification
NCT03520478.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Jiangsu Hengrui Pharmaceuticals Co., Ltd.
Disclosure
J. Lian, Q. Shi: Financial Interests, Personal, Full or part-time Employment: Jiangsu Hengrui Pharmaceuticals. All other authors have declared no conflicts of interest.
Resources from the same session
1816P - Combination treatment with radium-223 (223Ra) and enzalutamide (enza) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) in the REASSURE study
Presenter: Bertrand Tombal
Session: Poster session 14
1817P - A phase I/II efficacy and safety study of LAE001/prednisone and afuresertib in patients with metastatic castration-resistant prostate cancer (mCRPC) following 1-3 lines of standard of care
Presenter: Elan Diamond
Session: Poster session 14
1818P - Final results from a randomized phase II study of cabazitaxel (CBZ) versus an androgen receptor targeted agent (ARTA) in patients with poor-prognosis castration-resistant prostate cancer (mCRPC)
Presenter: Kim van der Zande
Session: Poster session 14
1819P - PSMA-BAT: Prospective biomarker trial of patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) undergoing bipolar androgen therapy (BAT)
Presenter: Aline Lara Gongora
Session: Poster session 14